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A Novel Bioresorbable Polymer
Paclitaxel-Eluting Stent for the Treatment
of Single and Multivessel Coronary Disease
Primary Results of the COSTAR (Cobalt Chromium Stent
With Antiproliferative for Restenosis) II Study
Mitchell W. Krucoff, MD, FACC,* Dean J. Kereiakes, MD, FACC,† John L. Petersen, MD,*
Roxana Mehran, MD,‡ Vic Hasselblad, PHD,* Alexandra J. Lansky, MD,§
Peter J. Fitzgerald, MD, PHD, FACC, Jyotsna Garg, MS,* Mark A. Turco, MD,¶
Charles A. Simonton III, MD, FACC,# Stefan Verheye, MD, PHD,** Christophe L. Dubois, MD,††
Roger Gammon, MD,‡‡ Wayne B. Batchelor, MD, MHS,§§ Charles D. O’Shaughnessy, MD,
James B. Hermiller, JR, MD,¶¶ Joachim Schofer, MD,## Maurice Buchbinder, MD, FACC,***
William Wijns, MD, PHD,††† for the COSTAR II Investigators Group
Durham and Charlotte, North Carolina; Cincinnati and Elyria, Ohio; New York, New York;
Stanford and La Jolla, California; Washington, DC; Antwerp, Leuven, and Aalst, Belgium; Austin, Texas;
Tallahassee, Florida; Indianapolis, Indiana; and Hamburg, Germany
Objectives The aim was to compare safety and effectiveness of the CoStar drug-eluting stent (DES) (Conor MedSystems,
Menlo Park, California) with those of the Taxus DES (Boston Scientific, Maple Grove, Minnesota) in de novo
single- and multivessel percutaneous coronary intervention (PCI).
Background Paclitaxel elution from a stent coated with biostable polymer (Taxus) reduces restenosis after PCI. The CoStar DES is
a novel stent with laser-cut reservoirs containing bioresorable polymer loaded to elute 10 g paclitaxel/30 days.
Methods Patients undergoing PCI for a single target lesion per vessel in up to 3 native epicardial vessels were randomly
assigned 3:2 to CoStar or Taxus. Primary end point was 8-month major adverse cardiac events (MACE), defined
as adjudicated death, myocardial infarction (MI), or clinically driven target vessel revascularization (TVR).
Protocol-specified 9-month angiographic follow-up included 457 vessels in 286 patients.
Results Of the 1,700 patients enrolled, 1,675 (98.5%) were evaluable (CoStar  989; Taxus  686), including 1,330 (79%)
single-vessel and 345 (21%) multivessel PCI. The MACE rate at 8 months was 11.0% for CoStar versus 6.9% for
Taxus (p  0.005), including adjudicated death (0.5% vs. 0.7%, respectively), MI (3.4% vs. 2.4%, respectively), and
TVR (8.1% vs. 4.3%, respectively). Per-vessel 9-month in-segment late loss was 0.49 mm with CoStar and 0.18 mm
with Taxus (p  0.0001). Findings were consistent across pre-specified subgroups.
Conclusions The CoStar DES is not noninferior to the Taxus DES based on per-patient clinical and per-vessel angiographic
analyses. The relative benefit of Taxus is primarily attributable to reduction in TVR. Follow-up to 9 months
showed no apparent difference in death, MI, or stent thrombosis rates. (J Am Coll Cardiol 2008;51:1543–52)
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The COSTAR II Study Primary Results April 22, 2008:1543–52Currently available drug-eluting
stents (DES) reduce restenosis
by inhibiting fibromuscular hy-
perplasia through targeted deliv-
ery of cytostatic drugs, such as
sirolimus or paclitaxel, from sur-
face coatings using durable poly-
mers (1,2). Concerns with such
first generation DES include in-
frequent but catastrophic late
stent thrombosis (3–5). Al-
though the cause of late stent
thrombosis is likely multifacto-
rial, durable polymer surface
coatings may play a role (6–8).
The CoStar (Conor MedSys-
tems, Menlo Park, California)
stent is a novel cobalt chromium
alloy DES platform designed to
elute paclitaxel without the use
of a surface polymer coating via
multiple laser-cut reservoirs
within the stent struts, which are
lled with a bioresorbable poly–lactic-co-glycolic acid
PLGA) polymer. After drug delivery and subsequent com-
lete polymer bioresorption, only the biologically inert
are-metal platform remains (Fig. 1). Reduction of tissue
xposure to polymer on stent implantation and elimination
f long-term (6 months) polymer exposure compared with
urable polymer surface-coated stents, such as Taxus (Bos-
on Scientific, Maple Grove, Minnesota), in theory might
avorably influence both short- and long-term inflammatory
nd thrombogenic events. Drug dose, direction (luminal vs.
bluminal), and kinetics of delivery are varied by drug-
olymer mixing on a reservoir-by-reservoir basis. The pre-
ision of these variations in drug delivery has been shown to
each biologically meaningful proportions in several inde-
Abbreviations
and Acronyms
CEC  clinical events
committee
DES  drug-eluting stent(s)
ECG  electrocardiography/
electrocardiogram
FDA  Food and Drug
Administration
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PLGA  poly–lactic-
co-glycolic acid
QCA  quantitative
coronary angiography
TVR  target vessel
revascularization
Figure 1 The CoStar Stent
The CoStar stent reservoir technology at 7 days and at 6 months.endent human trials, from which the 10 g/30 day
rug–PLGA reservoir load was selected based on the
ssociated angiographic late lumen loss at 4 to 12 months
9–11). Such precision in a lower range of paclitaxel dosing
n theory might provide similar efficacy but greater safety
argin in settings such as provisional stent overlap com-
ared with the higher dose delivered with the Taxus stent.
The COSTAR (Cobalt Chromium Stent With Antipro-
iferative for Restenosis) II study was designed to compare
he 8-month clinical outcomes of patients with both single-
nd multivessel coronary stenoses undergoing elective per-
utaneous coronary intervention (PCI) with either the
oStar or the Taxus DES. In addition, the biological
ehavior of vessels treated with each of these stents was
xamined in smaller cohorts, in whom protocol-specified
-month angiography was performed.
ethods
tudy design and population. The COSTAR II study
esign has been previously described in detail (12). In
ummary, COSTAR II was a multicenter, prospective,
ingle-blind, 3:2 (CoStar:Taxus) randomized study testing
oninferiority of the CoStar versus the Taxus paclitaxel
ES. In total, 1,700 patients were enrolled from 71 sites in
he U.S., Germany, Belgium, and New Zealand. Anatomic
ligibility required a de novo single target lesion of 50%
ut 99% stenosis in 1, 2, or 3 native epicardial coronary
rteries, with a reference vessel diameter from 2.5 to 3.5 mm
nd a lesion length of 30 mm that could be covered with
single stent. Anatomic exclusion criteria included ostial
esions, left main coronary disease of 50% stenosis, bifur-
ation lesions with 2 mm side branch involvement, total
cclusions, presence of a previously implanted DES proxi-
al to target lesion site, or 50% stenosis elsewhere in the
arget vessel. Clinical exclusion criteria included myocardial
nfarction (MI) within 72 h, prior revascularization within 3
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April 22, 2008:1543–52 The COSTAR II Study Primary Resultsonths, intolerance of clopidogrel or aspirin, known bleed-
ng diathesis, renal failure, left ventricular ejection fraction
25%, and contraindication to coronary artery bypass
urgery. Approval by each participating institution’s ethics
ommittee and informed consent from all patients were
equired and obtained.
Pre-specified subgroup analyses included patients with
ultivessel disease, patients with diabetes, and patients
equiring the provisional use of overlapping stents.
rotocol-mandated procedures. Repeat cardiac catheter-
zation was planned 9 months after the index procedure in
he first 250 patients enrolled with multivessel coronary
rtery disease and the first 100 patients with single-vessel
isease. Of these 100 single-vessel patients, the first 70 also
ad planned protocol-specified intravascular ultrasound
IVUS) evaluation at the 9-month catheterization. In addi-
ion, all patients with (provisional) overlapping stents also
nderwent repeat catheterization and IVUS at 9 months.
erial blood sampling for pK analysis was performed in 45
atients, including 16 patients with multivessel stenting. A
emoglobin A1c level was obtained at baseline in all
atients.
evice description. The CoStar stent is a 0.0035-inch
hick cobalt chromium alloy metal platform with nonde-
ormable strut segments that contain multiple laser-cut
oles (12). Each hole is individually filled with a bioabsorb-
ble PLGA polymer matrix combined with paclitaxel,
reating discrete reservoirs of drug elution. Abluminal
nd/or endoluminal direction, total drug dose, and kinetics
f drug delivery are controlled by programmed alterations in
he ratio of bioabsorbable polymer to drug for each reser-
oir. The PLGA polymer resorption is complete in the
orcine model by 180 days, thus leaving only the bare-metal
latform in perpetuity. Based on serial comparative human
tudies of paclitaxel dose, direction, and kinetics of delivery
9–11), the CoStar stent selected for the COSTAR II study
as the 10 g/30 day elution drug-polymer formulation.
andomization. Patients were randomly assigned 3:2 to
oStar or Taxus using an interactive voice randomization
ystem. Randomization was stratified by single- or multives-
el status. Patients were blinded to treatment assignment
ntil after completion of 1 year of follow-up.
tenting procedure. Antiplatelet therapy with a minimum
f 325 mg aspirin and a loading dose of at least 300 mg
lopidogrel, and intracoronary nitroglycerine for vessel siz-
ng before stent implantation were required. Pre-dilatation
f all lesions was also required. Planned use of a nonballoon
evice (rotational or directional atherectomy, laser, or any
napproved technology) was prohibited. Selection of U.S.
ood and Drug Administration (FDA)-approved anticoag-
lant therapy and use of adjunctive glycoprotein IIb/IIIa
nhibitors were at each operator’s discretion. High-pressure
ost-dilatation was recommended but not required. Intra-
ascular ultrasound other than the protocol-mandated use
escribed in the preceding was at the discretion of the
perator. sual antiplatelet therapy. Continuation of 325 mg aspirin
nd 75 mg clopidogrel daily for at least 6 months was
equired by protocol. For patients requiring warfarin sodium
herapy, an aspirin dose of 81 mg daily was recommended.
ecisions on interruption of dual antiplatelet therapy in case
f bleeding or urgent surgery or on extension of clopidogrel
herapy beyond 6 months were all managed clinically.
etails of all such decisions were systematically captured
nd collected by the data coordinating center.
linical follow-up. Pre-specified clinical follow-up in-
luded at index hospital discharge, 30 days, 8 months, and 1
ear. Patients with protocol-driven angiographic follow-up for
ny reason were required to have their 8-month clinical
valuation completed before their 9-month angiogram or
VUS.
ata management. All clinical data were double data
ntered into a Clintrials database at a central facility (Duke
linical Research Institute, Duke University Medical Cen-
er, Durham, North Carolina).
linical events committee. Events independently and
lindly reviewed by the clinical event committee (CEC)
Duke Clinical Research Institute, Duke University Medical
enter) included major adverse cardiac events (MACE),
tent thrombosis, and total occlusion. In conjunction with
DA approval of COSTAR II as an investigational device
xemption protocol, the definition of stent thrombosis was
aken from the Taxus IV study (2), as detailed subsequently.
he entire protocol was completed before the later publi-
ation of the consensus Academic Research Consortium
efinition (13) for stent thrombosis.
ore laboratories. ANGIOGRAPHY CORE LABORATORY. All
ngiograms were analyzed by an independent core labora-
ory (Quantitative Coronary Angiography [QCA] Core
aboratory, Cardiology Research Foundation, New York,
ew York). Angiograms were acquired using standardized
nstructions. The QCA was performed using the Cardio-
ascular Measurement System-Gradient Field Transform
lgorithm (Medis, Leiden, the Netherlands) (2). The min-
mum lumen diameter and the mean reference diameter,
btained from averaging 5-mm segments proximal and
istal to the target lesion location, were used to calculate the
iameter stenosis (diameter stenosis  [1  minimum
umen diameter/reference diameter] 100). Acute gain was
he change in minimum lumen diameter from baseline to
nal post-stent implantation angiogram; late loss was the
hange in minimum lumen diameter from the final post-
tent implantation angiogram to follow-up. Binary resteno-
is was defined as 50% diameter stenosis in the index
essel. All quantitative measurements were performed: 1)
ithin the stented segment (in-stent); 2) in-segment, span-
ing the stented segment plus the 5 mm proximal and distal
eristent areas; and 3) in the 5 mm proximal and distal
eristent areas immediately adjacent to the stent.
VUS CORE LABORATORY. Blinded IVUS analysis of 70
ubjects post-procedure and at 9 months was done by an
i
L
C
o
s
p
S
a
p
n
d
w
E
1
P
a
C
U
E
e
E
s
c
a
r
s
r
Q
s
d
t
n
l
c
c
w
i
r
t
c
t
a
t
p
a
c
d
f
S
(
l
p
p
r
s
l
a
c
d
v
i
p
t
t
a
i
p
u
o
f
S
M
e
b
d
(
w
c
s
l
M
d
(
a
p
p
s
e
d
b
r
g
i
p
t
n
T
a
a
l
b
s
p
I
t
s
c
1546 Krucoff et al. JACC Vol. 51, No. 16, 2008
The COSTAR II Study Primary Results April 22, 2008:1543–52ndependent core laboratory (Cardiovascular Core Analysis
aboratory, Stanford University Medical Center, Stanford,
alifornia). All images were reviewed by 2 independent
bservers, and adjudication of opinion was based on con-
ensus of these observers. Volumetric measurements were
erformed using planimetry software (echoPlaque, Indec
ystems, Santa Clara, California) as previously described
nd included persistent plaque volume, neointimal volume,
ercent neointimal obstruction, neointimal coverage, and
eointimal thickness (14). Incomplete stent apposition was
efined as 1 or more struts clearly separated from the vessel
all with evidence of blood speckles behind the strut.
LECTROCARDIOGRAPHY CORE LABORATORY. Standard
2-lead electrocardiograms (ECGs) were collected before
CI, before hospital discharge, and at 8-month follow-up
nd forwarded to an independent core laboratory (ECG
ore Laboratory, Duke Clinical Research Institute, Duke
niversity Medical Center, Durham, North Carolina). The
CGs were analyzed for new pathological Q waves by an
xperienced cardiologist blinded to treatment assignment.
nd points. The primary end point of the COSTAR II
tudy was 8-month MACE, defined as a hierarchical
omposite of cardiac or unknown cause of death, Q-wave
nd non–Q-wave MI, and clinically driven target vessel
evascularization (TVR). This time point was selected
pecifically to allow completion of all clinical outcomes
eporting before any protocol (9 month) catheterizations.
-wave MI was defined as: 1) clinical presentation with
igns or symptoms of MI with new pathological Q waves as
etermined by the ECG core lab or independent review of
he CEC in the absence of timely cardiac enzyme data; or 2)
ew pathological Q waves as determined by the ECG core
ab or independent review of the CEC and elevation of
ardiac enzymes. Non–Q-wave MI was defined as elevated
reatine kinase (CK) 2 times the upper limit of normal
ith elevated CK-MB in the absence of any new patholog-
cal Q waves. “Clinically driven TVR” was defined as a
evascularization of the target vessel with: 1) anginal symp-
oms and/or functional ischemia with a 50% stenosis by
ore lab QCA; or 2) revascularization of 70% stenosis by
he core lab QCA. All deaths and MI events were counted
s MACE events unless the CEC unequivocally attributed
hem to either a nontarget vessel or noncardiac cause. The
rimary angiographic end point was per-vessel 9-month
ngiographic in-segment late lumen loss.
Secondary end points included the individual MACE
omponents, 30-day and 12-month MACE, clinically
riven target lesion revascularization, and target vessel
ailure, as were reported in the pivotal Taxus IV study (2).
econdary technical end points included device success
final stenosis of 50% using the assigned device only),
esion success (final stenosis of50% using any device), and
rocedure success (final stenosis of 50% with no
rocedure-related MACE). Stent thrombosis was catego-
ized as acute (before leaving the catheterization laboratory), mubacute (after the index procedure and within 30 days), and
ate (after 30 days). Acute stent thrombosis was defined as
brupt vessel closure of the treatment site resulting in
linical manifestations of ischemia and angiographic evi-
ence of occlusion or flow-limiting thrombosis in a treated
essel, in which the investigational device was successfully
mplanted, that occurred after the procedure but before the
atient left the catheterization laboratory. Subacute stent
hrombosis was defined as abrupt vessel closure of the
reatment site producing clinical manifestations of ischemia
nd occlusion occurring after the patient left the catheter-
zation laboratory but within 30 days of the interventional
rocedure. Late stent thrombosis was defined as MI attrib-
table to the target vessel, with angiographic documentation
f thrombus or total occlusion at the target lesion 30 days
ollowing successful implantation of the device.
tatistical analysis. The primary end point (8-month
ACE) analysis (12) was a noninferiority analysis using
ither the relative risk or the absolute difference in rates
etween the CoStar stent rates and the Taxus stent rates,
epending on the actual MACE rate observed in the Taxus
control) arm. If the actual MACE rate in the Taxus arm
as 10%, then the observed relative risk was to be
ompared with a relative delta of 1.5, calculated using
tatistical software (Proc Genmod, SAS, Cary, North Caro-
ina) using a log link function. If the actual 8-month
ACE rate in the Taxus arm was 10%, then an absolute
elta of 5% was to be used, calculated using software
StatXact, Cytel, Cambridge, Massachusetts) to provide
symptotic and exact confidence intervals for a difference in
roportions.
In conjunction with discussions with the FDA for this
ivotal study, a series of consistency analyses were pre-
pecified to provide “reasonable assurance” of safety and
ffectiveness of the CoStar stent. As has previously been
etailed (12), these consistency analyses were additive and
ased on confidence intervals specifically calculated with
egard to the denominator of each subgroup (e.g., angio-
raphic cohort, single-vessel cohort), not as serial compar-
sons per se. Thus, if 8-month MACE rates from the
rimary end point analysis met the boundaries specified,
hen 2 consistency analyses were to be computed to confirm
oninferiority using the pre-specified confidence intervals.
he 9-month angiographic in-segment late loss was to be
nalyzed on a per-vessel basis using the protocol-specified
ngiographic cohort. An absolute difference in 9-month late
oss between the Taxus group and the CoStar group was to
e estimated. A 95% confidence interval was to be con-
tructed around this estimate using a statistical analysis
rocedure (Proc Mixed, SAS) with the repeated statement.
f this confidence interval fell completely below 0.32 mm,
hen noninferiority of the CoStar stent relative to the Taxus
tent would be confirmed by the late loss observations. If the
onfidence interval overlapped or fell completely above 0.32
m then noninferiority would not be confirmed.
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April 22, 2008:1543–52 The COSTAR II Study Primary ResultsFinally, if the preceding 2 conditions were met, then a
hird confirmatory test for angiographic late loss was to be
erformed using only the single-vessel stratum of angio-
raphic cohort patients, using the same analytic methods as
he preceding but with the relative delta set at 1.65 and the
bsolute delta set at 7% to accommodate the smaller
enominator of patients.
If all 3 conditions described were met (per-patient
-month MACE, per-vessel late lumen loss in entire
ngiographic cohort, and per-vessel late lumen loss in
ingle-vessel angiographic cohort), then the CoStar device
as to be declared to be noninferior to the Taxus device.
In the absence of any previous trial comparing the CoStar
tent with an FDA-approved bare-metal stent, a final step
as included in the primary statistical analysis plan: an
mputed placebo calculation (12). For this analysis, the
rimary end point was estimated for a bare-metal stent
gainst the experimental CoStar DES in the single-vessel
isease population, because bare-metal stent data versus
axus DES was only available for single-vessel disease
atients at the time COSTAR II was designed. This
nalysis used the formulas and logic previously detailed by
asselblad and Kong (15). The hypothesis was tested in the
elative risk space (CoStar vs. placebo) regardless of the
OSTAR II Taxus arm outcome rate. The estimate and
ariance used for the effect of standard treatment relative to
lacebo was taken from previously published pooled data for
he Taxus IV (2), V (16), and VI (17) studies. If the
onfidence interval for the estimate of experimental treat-
ent relative to placebo was completely to the left of 1.0, it
ould be taken to indicate that the CoStar stent was better
han a bare-metal stent would have been.
Continuous data are presented as means, and categorical
ariables are presented as percentages, unless otherwise
oted. Selected baseline characteristics and clinical and
ngiographic outcomes are compared between treatment
roups by the chi-square test in case of discrete variables and
test in case of continuous variables. A p value of0.05 was
onsidered to be statistically significant. No statistical ad-
ustment was made for multiple comparisons. All analyses
ere done using SAS version 8.0 or higher statistical
oftware.
esults
atient and lesion characteristics. Of the 1,700 patients
andomly assigned, 1,675 (98.5%) were evaluable and con-
tituted the primary study population (Fig. 2). The 25
erandomized patients were excluded because: 1) angio-
raphic inclusion criteria could not be confirmed at the time
f the index PCI procedure; or 2) the study-assigned stent
as never removed from the packaging or advanced beyond
he guide catheter. Of the 1,675 patients, 989 were ran-
omly assigned to receive treatment with the CoStar DES
nd 686 with the Taxus DES in the asymmetric 3:2 design.
linical descriptors and target lesion characteristics were mvenly distributed across treatment groups (Table 1). Of the
,675 patients, 1,330 (79%) had single-vessel intervention
nd 345 (21%) had multivessel intervention. In total, 2,058
arget lesions were treated, 1,212 (59%) with CoStar and
46 (41%) with Taxus. Procedural glycoprotein IIb/IIIa
nhibitors were used in 20.5% of all patients (20.2% for
oStar, 20.9% for Taxus).
rocedural characteristics. On a per-vessel analysis, device
uccess was analyzable in 2,049 (99.6%) of 2,058 lesions. Of
hese 2,049, device success was achieved in 1,173 (97.3%) of
,205 lesions with CoStar (single-vessel 794 of 813 [97.6%],
ultivessel 379 of 392 [96.7%]) and in 825 (97.7%) of 844
esions with Taxus (single-vessel 539 of 552 [97.6%],
ultivessel 286 of 292 [97.9%]), and lesion success was
chieved in 100% and 99.9%, respectively. On a per-patient
nalysis, procedural success was achieved in 957 (97.4%) of
83 patients with CoStar (single-vessel 770 of 786 [97.9%],
ultivessel 187 of 197 [94.9%]), and in 672 (98.2%) of 684
atients with Taxus (single-vessel 532 of 539 [98.7%],
ultivessel 140 of 145 [96.6%]). None of these differences
ere significant.
linical outcomes. Periprocedural/index hospitalization
ierarchical MACE was 2.6% with CoStar (0% death, 2.4%
I, 0.2% clinically driven TVR) and 1.6% with Taxus (0%
eath, 1.6% MI, 0% clinically driven TVR); p 0.160. The
ate of MACE at 30 days was 3.4% with CoStar (0% death,
.8% MI, 1.0% clinically driven TVR) and 1.9% with Taxus
0% death, 1.6% MI, 0.2% clinically driven TVR); p 
.063. In patients with single-vessel disease, periprocedural/
ndex hospitalization hierarchical MACE was 2.0% with
oStar (0% death, 1.9% MI, 0.1% clinically driven TVR)
nd 1.3% with Taxus (0% death, 1.3% MI, 0% clinically
riven TVR); p  0.3131. The rate of MACE at 30 days
as 3.1% with CoStar (0% death, 2.4% MI, 1.0% clinically
riven TVR) and 1.5% with Taxus (0% death, 1.3% MI,
.2% clinically driven TVR); p  0.0711. In patients with
Figure 2 Patient Flow Diagram
Of the 1,700 patients randomly assigned, 1,675 were evaluable and
constituted the primary study population. IVUS  intravascular ultrasound.ultivessel disease, periprocedural/index hospitalization hi-
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The COSTAR II Study Primary Results April 22, 2008:1543–52rarchical MACE was 5.0% with CoStar (0% death, 4.5%
I, 1.0% clinically driven TVR) and 2.8% with Taxus (0%
eath, 2.8% MI, 0% clinically driven TVR); p  0.2977.
he rate of MACE at 30 days was 5.0% with CoStar (0%
eath, 4.5% MI, 1.0% clinically driven TVR) and 3.5% with
axus (0% death, 2.8% MI, 0.7% clinically driven TVR);
 0.4794. Table 2 shows MACE at 8 months, the
rimary study end point, and each of its components. The
ate of MACE was significantly lower with Taxus than with
oStar, a difference due predominantly to the difference in
linically driven TVR rates. At 8 months, both MI and
ortality rates were not significantly different. The MACE
o 8 months is shown discretely for both the single- and the
ultivessel subgroups (Table 2). The absolute difference
etween observed event rates between Taxus and Costar
roups with multivessel PCI is numerically larger than in
he single-vessel cohort, but with the smaller number of
atients does not reach statistical significance.
The temporal distribution of hierarchical MACE and its
omponent events are shown in Kaplan-Meier curves to
ompleted 9-month follow-up in Figure 3. The impact of
linical Descriptors and Lesion Characteristics
Table 1 Clinical Descriptors and Lesion Characteristics
Total
(n  1,675)
CoStar*
(n  989)
Taxus*
(n  686)
Patient characteristics, %
(unless otherwise specified)
Male 72.3 73.1 71.1
Age, mean  SD (yrs) 63.6  10.7 63.5  10.8 63.7  10.6
Prior MI 26.9 26.3 27.7
Prior PCI 33.1 33.5 32.7
Prior CABG 6.2 6.4 6.0
Diabetes mellitus 28.0 27.4 28.9
IDDM* 25.0 27.7 21.3
Hyperlipidemia 79.8 80.5 78.9
Hypertension 77.8 77.9 77.7
Unstable angina 30.5 29.4 32.1
Current smoker 20.8 20.1 21.9
LVEF, mean  SD (%) 58.2  11.7 58.0  11.6 58.5  11.8
Multivessel treatment 20.6 20.2 21.1
Lesion characteristics, %
(unless otherwise specified)
RVD, mean  SD (mm) 2.76  0.47 2.77  0.47 2.75  0.48
MLD, mean  SD (mm) 0.87  0.41 0.86  0.40 0.89  0.41
B2/C lesion class 60.0 58.9 61.5
Moderate/heavy calcification 25.6 25.8 25.3
LAD 40.1 39.9 40.3
Circumflex 27.9 27.9 30.6
RCA 31.0 32.2 29.2
Lesion length, mean  SD (mm) 15.2  6.5 15.4  6.5 15.1  6.5
Average stent diameter per
vessel, mean  SD (mm)
2.96  0.55 2.95  0.57 2.96  0.50
Total stented length,
mean  SD (mm)
20.5  7.6 20.7  7.8 20.1  7.4
Overlap stenting, n 168 108 60
For all comparisons, p  nonsignificant.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; IDDM  insulin-depe
yocardial infarction; MLD  minimal lumen diameter; PCI  percutaneous coronary interventio13 protocol catheterizations (100 single-vessel, 250 iultivessel, 168 patients with overlapped stents [60 with
axus, 108 with CoStar]) on TVR events from 8- to
-month follow-up can be discretely appreciated. In this
-month interval, additional MACE events produced an
bsolute increase in event rates of 2.4% in Taxus patients
nd 3.7% in CoStar patients, numerically increasing the
ifference between the 2 cohorts. The Kaplan-Meier
urves of death and Q-wave MI show no significant
ifferences at any time, whereas the clinically driven TVR
urves begin to separate between 30 and 90 days after
ndex PCI.
Odds ratios of 8-month hierarchical MACE are shown
or all pre-specified subgroups in Figure 4. Differences do
ot reach statistical significance in many of the subgroups
wing to small denominators; however, numerical differ-
nces and trends consistently favor the Taxus treatment
roup.
er-vessel angiographic outcomes. Angiographic results
t 9 months from 456 lesions in 286 patients (262 lesions
oStar, 194 lesions Taxus) are shown in Table 2. Per-vessel
r Single-Vessel
n  789)
Taxus SingleVessel
(n  541)
CoStar Multivessel
(n  200)
Taxus Multivessel
(n  145)
72.1 69.3 77.0 77.9
3.4  10.8 63.4  10.6 64.0  10.8 64.8  10.2
26.5 28.3 25.5 25.5
35.0 34.4 27.5 26.2
7.0 6.7 4.0 3.4
27.0 29.0 29.0 28.3
26.3 21.2 32.8 22.0
81.6 80.2 76.0 73.8
77.3 78.6 80.0 74.5
28.9 31.6 31.5 33.8
20.7 22.2 18.0 20.7
7.9  11.5 58.7  11.6 58.1  12.0 57.8  12.2
0 0 100.0 100.0
.78  0.46 2.78  0.49 2.75  0.48 2.69  0.46
.86  0.40 0.88  0.42 0.87  0.41 0.90  0.41
61.0 64.6 54.5 55.6
25.0 25.3 27.6 25.4
41.9 41.3 35.9 38.2
26.3 27.8 31.1 35.8
31.8 30.9 33.1 25.9
.01  6.28 14.83  6.29 16.06  6.82 15.53  6.77
.96  0.58 2.96  0.58 2.68  0.44 2.64  0.41
.56  8.02 19.82  7.46 21.06  7.33 20.70  7.14
73 36 35 24
iabetes mellitus; LAD  left anterior descending; LVEF  left ventricular ejection fraction; MI 
 right coronary artery; RVD  reference vessel diameter.CoSta
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April 22, 2008:1543–52 The COSTAR II Study Primary Resultsinary restenosis were all significantly better in the Taxus
roup compared with the CoStar group.
tent thrombosis. Both overall and time-related incidence
f protocol-defined stent thrombosis are shown in Table 3.
he 1 patient with acute thrombosis had coronary perfora-
ion during the index procedure, which was treated with a
tent graft (Jomed International, Helsingborg, Sweden).
ecurrent instability while still in hospital led to recatheter-
zation, which showed thrombus on the stent graft that was
reated medically without further complications. Of the 4
oStar patients with subacute stent thromboses, 1 (throm-
osis on day 3) was found to be dual antiplatelet therapy
esistant, 2 (thromboses on days 6 and 9) were clopidogrel
oncompliant, and antiplatelet therapy compliance was
ndeterminate in 1 patient. Both patients who suffered late
hrombosis did so within days of stopping their clopidogrel
day 177 for CoStar, day 232 for Taxus). All stent throm-
oses were associated with MI, none with death.
mputed placebo. The relative risk of 8-month MACE
utcomes with the CoStar stent versus the imputed placebo
f the Express bare-metal stent is shown in Figure 5.
onfidence intervals of CoStar 8-month MACE cross the
nity line, suggesting that use of the CoStar stent produced
o significant difference from the imputed outcomes with a
are-metal stent placebo.
iscussion
n this prospective, randomized, multicenter study of 2
aclitaxel-eluting stent platforms, per-patient primary clin-
cal outcomes at 8 months and per-vessel angiographic end
oints at 9 months demonstrated significant differences
etween the Taxus DES versus the CoStar DES, with the
linical and Angiographic End Points
Table 2 Clinical and Angiographic End Points
Parameter
CoStar
(n  989)
Taxus
(n  686) p Value
8-month clinical end points (%)
All MACE 11.0 6.9 0.005
Single-vessel MACE 9.9 6.1 0.015
Multivessel MACE 15.4 9.7 0.125
Death 0.5 0.7 0.541
MI 3.4 2.4 0.242
Clinically-driven TVR 8.1 4.3 0.002
9-month angiographic end points
Late loss (mm)
In-stent 0.64 0.26 0.0001
In-segment 0.49 0.18 0.0001
Diameter stenosis (%)
In-stent 25.32 12.83 0.0001
In-segment 31.89 23.95 0.0001
BAR (%)
In-stent 17.9 4.1 0.0001
In-segment 18.7 6.7 0.0002
AR  binary angiographic restenosis; MACE  major adverse cardiac events; MI  myocardial
nfarction; TVR  target vessel revascularization.esult that it cannot be concluded that CoStar DES isoninferior to Taxus DES. Divergence between the clinical
vent curves begins around 3 months, is numerically exag-
erated by oculostenotic events at 9 months, and is predom-
nantly driven by TVR (MI and death rates remain essen-
ially the same between devices over that time). This
Figure 3 MACE
(A) 240- to 270-day hierarchical MACE. (B) 240- to 270-day death and Q-wave
MI. (C) 240- to 270-day clinically driven TVR. MACE  major adverse cardiac
events; MI  myocardial infarction; TVR  target vessel revascularization.
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The COSTAR II Study Primary Results April 22, 2008:1543–52trongly suggests the mechanistic hypothesis that fibrointi-
al hyperplasia resulting in in-stent restenosis is greater
ith the CoStar stent than with the Taxus stent. The
er-vessel angiographic findings at 9 months also support
his mechanistic explanation. Finally, the imputed placebo
alculation implies that the CoStar stent is not superior to
are-metal stents, which have been shown to have signifi-
antly higher in-stent restenosis rates than the Taxus stent
n randomized controlled clinical trials (2).
Secondary analyses of multiple subgroups, including the 3
re-specified groups (single- vs. multivessel disease, diabe-
es, and patients with overlapping stents), were highly
onsistent with the primary study results. No significant
ncrease in the risk of death, MI, or stent thrombosis was
ppreciated in any subgroup.
Figure 4 MACE in Subgroups
Eight-month hierarchical MACE in pre-specified subgroups. D/C  discontinued;
IDDM  insulin-dependent diabetes mellitus; LAD  left anterior descending
artery; MACE  major adverse cardiac events; MVD  multivessel disease;
NIDDM  noninsulin-dependent diabetes mellitus; RVD  reference vessel
diameter; Rx  prescription; SVD  single-vessel disease.
rotocol-Defined Stent Thrombosis
Table 3 Protocol-Defined Stent Thrombosis
CoStar Taxus p Value
Acute (24 h) 0.1% (1) 0.0% (0) NS
Subacute (1–30 days) 0.4% (4) 0.0% (0) NS
Late (1–9 months) 0.1% (1) 0.1% (1) NS
Total stent thrombosis 0.6% (6) 0.1% (1) 0.25aS  not significant.The CoStar DES incorporates a number of unique
eatures with theoretic appeal compared with the Taxus
tent (12). Whereas the Taxus DES was developed by
pplying a surface coating of durable polymer to the
are-metal Express platform, the CoStar stent was designed
pecifically for drug delivery via individual wells filled with
rug and polymer (12). Initial studies that evaluated the
ptimal drug load and kinetics of paclitaxel delivery using
he CoStar platform were encouraging. The PISCES (Pac-
itaxel In-Stent Controlled Elution Study) study examined 6
ifferent drug, direction, and duration of elution configura-
ions, and the COSTAR I study independently evaluated
ose optimization using 3 configurations (9,10). Both early
4 months) and late (12 months) angiographic surrogate
easures suggested that the abluminal unidirectional 10 g/30
ay and 30 g/30 day stent loads effectively preserved in-
egment and in-stent late lumen loss (9,10). These 2 formu-
ations were then tested head to head in the EUROSTAR
European Cobalt Stent With Antiproliferative for Restenosis)
rial, where the 10 g/30 day platform was found to result
n lower levels of late lumen loss in human subjects (11).
ased on this series of human dose-finding investigations,
he 10 g/30 day load was selected for the pivotal
OSTAR II study.
Despite theoretic design novelty and the consistent legacy
f previous small trial performance with 4- to 12-month
n-segment late loss values of 0.3 mm with the 10 g/30
ay formulation, the results of the pivotal COSTAR II trial
erve as a reminder of the importance of adequately sized
nd well designed trials conducted in contemporary patient
ohorts (9–11). Notably, in COSTAR II, the CoStar stent
erformed worse than in preceding trials and the Taxus
tent performed better than in its pivotal study (Taxus IV),
espite the more complex patient cohort in COSTAR II.
otential explanations for under- or over-performance are
peculative, but include small previous study size with wide
onfidence intervals, differences in device manufacturing
rocess (CoStar), and operator familiarity and learning
urve (Taxus).
The COSTAR II study represents the actual implemen-
ation of a different set of key principles outlined in the early
nticipation of the challenges of active-control studies of
ES. Instead of emphasizing the use of surrogate angio-
raphic measures in simple patients, COSTAR II enrolled
Figure 5 Relative Risk
Relative risk of CoStar versus imputed
placebo 8-month major adverse cardiac events.more complex (“enriched”) patient population in whom a
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April 22, 2008:1543–52 The COSTAR II Study Primary Resultsigher density of clinical events would be expected (18).
his strategy supports a logistically feasible clinical trial that
lso provides pre-market data with greater relevance to
eal-world post-market use (18). Furthermore, by enriching
he angiographic cohort with multivessel patients, the eth-
cal and logistic issues associated with mandated repeat
atheterization were minimized, which is a key feature when
atients have the alternative of receiving an approved DES
ithout participation in the research study. Indeed, the
OSTAR II trial has the smallest percentage of patients
ubjected to protocol recatheterization of any published
ivotal DES study. In addition, by completing the clinical
utcome evaluation 30 days before protocol-specified cath-
terization, the impact of oculostenotic events could be
iscretely appreciated. A number of these study design
eatures are among recommendations for future DES piv-
tal trials (19).
The statistical analysis of an enriched population in an
ctive control noninferiority study design is unique as well.
t the time COSTAR II was being planned, multivessel
tenting with the Taxus DES was widely practiced in
ost-market use, but it was not an approved indication for
he device and had not been reported in a randomized
linical trial. Thus, the COSTAR II control group also
epresented an “exploratory” population (e.g., one without a
learly definable predicate) (12). The statistical analysis plan
eveloped a noninferiority delta as a relative risk to the
ctual observed event rate in the control group over a range
f possibilities and supported the relative risk delta with an
mputed placebo calculation to ensure that the confidence
ntervals at the high end of the delta would not reach the
owest event rates expected from bare-metal stents.
tudy limitations. There are a number of limitations
orth noting from this report. Initially, the hope was to
nroll 50% multivessel patients; however, this proved to be
nfeasible. Nonetheless, the 20% enrolled represent the first
dvance to more “enriched” populations in pivotal DES
tudies. In addition to the multivessel group, there are many
ther key subgroups that remain relatively underpowered for
oninferiority comparisons, despite the fact that COSTAR
I is larger than any previously reported pivotal DES trial.
he IVUS findings in the very small number of single-vessel
nd overlap cases acquired are not included in the present
eport, and they might offer further mechanistic insights
nto the behavior of both CoStar and Taxus stents in these
opulations. However, the clinical and angiographic find-
ngs are all so consistent that it is unlikely that IVUS would
ffect any of the conclusions from this primary study report.
Although clearly not noninferior, safety issues between
axus and the CoStar DES platforms remain of interest. By
months of follow-up no differences in safety parameters
ere observed between devices. The COSTAR II study was
esigned before widespread awareness of infrequent but
atastrophic events, such as late stent thrombosis, and is not
owered for such comparisons, particularly within such a
hort follow-up period. Further insights may be gained Bhen longer-term follow-up is completed and integrated
ith the detail of actual duration of dual antiplatelet
herapy, therapy interruption, and so on. Finally, although
he definition of stent thrombosis used in COSTAR II was
eveloped primarily for comparability with Taxus IV, the
ubsequent emergence of the Academic Research Consor-
ium stent thrombosis definitions may make readjudication
f these events useful to support comparability with other
ES platform experiences (13).
onclusions
he COSTAR II study demonstrates that it cannot be
oncluded that the CoStar DES is noninferior in clinical
nd angiographic performance compared with the Taxus
ES. The relative benefit attributable to the Taxus stent is
redominantly due to lower rates of clinically driven TVR,
ith no differences observed in the incidences of death, MI,
r stent thrombosis by the end of 9 months’ follow-up.
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